Energy MetabolismMITOCAFFEINENCT07873047
Acute Effects of Caffeine on Mitochondrial Function in Peripheral Blood Mononuclear Cells
A study testing Caffeine (5 mg/kg) in people with Energy Metabolism, run by Pontificia Universidad Catolica de Chile.
Trial summary
This randomized, double-blind, placebo-controlled crossover study will evaluate the acute effects of caffeine consumption on substrate utilization, resting energy metabolism, and mitochondrial function in peripheral blood mononuclear cells (PBMCs) in healthy young adults. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Energy Metabolism
- What is being tested?
- Caffeine (5 mg/kg)
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 12 participants
- Where
- No sites listed yet
- Study dates
- Sep 2026to Mar 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Healthy adults aged 18 to 65 years.
- Body mass index between 18.5 and 27 kg/m².
- Non-smokers.
- Habitual caffeine intake of 200 mg/day or less.
- No use of medications or supplements known to affect energy metabolism.
- Able and willing to provide written informed consent.
Who cannot join
- Chronic metabolic, cardiovascular, or inflammatory disease.
- Use of antioxidant supplements or ergogenic substances within the 4 weeks before participation.
- Known hypersensitivity to caffeine or history of adverse effects after caffeine consumption.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Efectos Agudos Del Consumo de cafeína en el Uso de Sustratos y en la función Mitocondrial en células Mononucleares de Sangre periférica
This randomized, double-blind, placebo-controlled crossover study will evaluate the acute effects of caffeine consumption on substrate utilization, resting energy metabolism, and mitochondrial function in peripheral blood mononuclear cells (PBMCs) in healthy young adults. Approximately 10 healthy men and women aged 18 to 35 years will participate. Each participant will complete two experimental visits, receiving caffeine in one visit and placebo in the other, in randomized order. The two visits will be separated by a 48-hour washout period. Participants will attend the laboratory after an overnight fast of approximately 14 hours and will abstain from caffeine, alcohol, and intense physical activity before each visit. Resting gas exchange will be measured before ingestion and 1 and 3 hours after caffeine or placebo administration. Blood samples will be collected at the same time points to isolate PBMCs and obtain plasma for metabolic analyses. Mitochondrial function will be assessed by high-resolution respirometry, and mitochondrial dynamics and morphology will be evaluated using protein analyses and transmission electron microscopy. The study will determine whether acute caffeine consumption alters resting substrate utilization and mitochondrial responses in PBMCs in healthy young adults.
Read the detailed description
Caffeine is one of the most widely consumed psychoactive compounds and is commonly used because of its stimulant and metabolic effects. By antagonizing adenosine receptors, caffeine may increase sympathetic activity, promote the mobilization of free fatty acids, and alter energy metabolism. Mitochondria are central regulators of cellular energy production, and mitochondrial function and dynamics may respond to changes in nutrient availability and metabolic stress. Peripheral blood mononuclear cells (PBMCs) provide a minimally invasive cellular model that may reflect systemic metabolic responses in humans. However, the acute effects of caffeine on substrate utilization and mitochondrial function and dynamics in human PBMCs remain insufficiently characterized.
This study will use a randomized, double-blind, placebo-controlled, crossover design. Approximately 10 healthy adults aged 18 to 35 years will be recruited. Eligible participants will have a body mass index between 18.5 and 27 kg/m², will not smoke, will not be chronic caffeine consumers exceeding 200 mg/day, and will not use medications or supplements known to affect energy metabolism. Individuals with chronic metabolic, cardiovascular, or inflammatory diseases; recent use of antioxidant supplements or ergogenic substances; or known caffeine hypersensitivity or previous adverse reactions to caffeine will be excluded.
Each participant will complete two experimental visits separated by a 48-hour washout period. Before each visit, participants will avoid caffeine, alcohol, and intense physical activity for 24 hours and will attend the laboratory after an overnight fast of approximately 14 hours. After 30 minutes of supine rest under thermoneutral conditions, resting gas exchange will be measured for 30 minutes using a breath-by-breath pulmonary gas-analysis system. A weight-adjusted dose of caffeine, corresponding to approximately 4 to 6 mg/kg of body weight, or placebo will then be administered with approximately 250 mL of water. Resting gas exchange and venous blood samples will be obtained before ingestion and 1 and 3 hours after ingestion.
Blood samples will be collected from the antecubital vein by qualified healthcare personnel. PBMCs will be isolated using a density-gradient method, and plasma will be obtained for analysis of glucose, lactate, lipid profile, insulin, and non-esterified fatty acids. Mitochondrial respiration in PBMCs will be assessed using high-resolution respirometry, including basal respiration, maximal respiratory capacity, and mitochondrial ATP-linked respiration. Mitochondrial biogenesis, mass, fusion, and fission will be evaluated by assessing PGC-1α, TOM20, MFN1, OPA1, DRP1, and FIS1 protein expression. Mitochondrial morphology will be examined using transmission electron microscopy.
The primary objective is to determine the acute effect of caffeine on mitochondrial function in PBMCs. Additional objectives are to evaluate its effects on resting energy metabolism, substrate utilization, plasma metabolic markers, mitochondrial dynamics, and mitochondrial morphology. Participants will receive a snack at the end of each experimental visit.
- Conditions
- Energy Metabolism
- Being tested
- Caffeine (5 mg/kg), Placebo
- Keywords
- caffeine, energy metabolism, sustrate utilization, resting metabolic rate, peripheral blood mononuclear cells, PBMC, mitochondrial function, mitochondrial respiratoration, lipid oxidation, healthy young adults, randomized crossover trial, double-blind placebo-controlled trial
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Caffeine (5 mg/kg)Dietary supplement
Caffeine will be administered orally as a single weight-adjusted dose of 5 mg/kg body weight in an opaque capsule with approximately 250 mL of water. It will be administered immediately after baseline measurements during one experimental visit. Participants will receive caffeine in one of the two study periods according to the randomized crossover sequence. Resting gas exchange and venous blood samples will be collected before ingestion and 1 and 3 hours after ingestion.
PlaceboOther
The placebo will consist of an inert substance administered orally in an opaque capsule matched in appearance to the caffeine capsule, with approximately 250 mL of water. It will be administered immediately after baseline measurements during one experimental visit. Participants will receive placebo in one of the two study periods according to the randomized crossover sequence.
| Study group | Role | What they receive |
|---|---|---|
| Caffeine followed by Placebo | Experimental | Participants assigned to this sequence will receive caffeine during the first experimental visit and placebo during the second experimental visit. The visits will be separated by a 48-hour washout period. Resting gas exchange and venous blood samples will be collected before intervention ingestion and 1 and 3 hours after ingestion during each study period. Receives: Dietary Supplement: Caffeine (5 mg/kg); Other: Placebo |
| Placebo followed by Caffeine | Placebo comparator | Participants assigned to this sequence will receive placebo during the first experimental visit and caffeine during the second experimental visit. The visits will be separated by a 48-hour washout period. Resting gas exchange and venous blood samples will be collected before intervention ingestion and 1 and 3 hours after ingestion during each study period. Receives: Dietary Supplement: Caffeine (5 mg/kg); Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Basal mitochondrial respiration in PBMCs
Basal mitochondrial respiration in peripheral blood mononuclear cells (PBMCs) will be assessed as part of a complete high-resolution mitochondrial respirometry protocol using the Oroboros O2k system. Basal oxygen consumption will be measured before addition of respiratory modulators and expressed as oxygen consumption rate in pmol O2/cells
Measured: Baseline, 1 hour, and 3 hours after caffeine or placebo ingestion during each study period
Maximal mitochondrial respiratory capacity in PBMCs
Maximal mitochondrial respiratory capacity will be determined as part of the complete high-resolution mitochondrial respirometry protocol in PBMCs using the Oroboros O2k system. It will be expressed as maximal oxygen consumption rate in pmol O2/cells
Measured: Baseline, 1 hour, and 3 hours after caffeine or placebo ingestion during each study period
Secondary outcomes (9)
Resting energy expenditure and substrate utilization
Resting energy expenditure will be estimated from oxygen consumption and carbon dioxide production measured during 30 minutes of resting gas exchange. The outcome will be expressed in kcal/day.
Measured: Baseline, 1 hour, and 3 hours after caffeine or placebo ingestion during each study period
Fat oxidation rate during resting gas exchange
Fat oxidation rate will be estimated from oxygen consumption and carbon dioxide production measured during resting gas exchange. The outcome will be expressed in g/min.
Measured: Baseline, 1 hour, and 3 hours after caffeine or placebo ingestion during each study period
Carbohydrate oxidation rate during resting gas exchange
Carbohydrate oxidation rate will be estimated from oxygen consumption and carbon dioxide production measured during resting gas exchange. The outcome will be expressed in g/min.
Measured: Baseline, 1 hour, and 3 hours after caffeine or placebo ingestion during each study period
Plasma glucose concentration
Plasma glucose concentration will be measured from venous blood samples using a clinical laboratory assay. The outcome will be expressed in mg/dL.
Measured: Baseline, 1 hour, and 3 hours after caffeine or placebo ingestion during each study period
Plasma lactate concentration
Plasma lactate concentration will be measured from venous blood samples using a clinical laboratory assay. The outcome will be expressed in mM
Measured: Baseline, 1 hour, and 3 hours after caffeine or placebo ingestion during each study period
Plasma insulin concentration
Plasma insulin concentration will be measured from venous blood samples using a clinical laboratory assay. The outcome will be expressed in µU/mL
Measured: Baseline, 1 hour, and 3 hours after caffeine or placebo ingestion during each study period
Plasma non-esterified fatty acid concentration
Plasma non-esterified fatty acid concentration will be measured from venous blood samples using a quantitative laboratory assay. The outcome will be expressed in mM
Measured: Baseline, 1 hour, and 3 hours after caffeine or placebo ingestion during each study period
Mitochondrial dynamics-related protein expression in PBMCs
The expression of a prespecified panel of mitochondrial-related proteins in peripheral blood mononuclear cells (PBMCs) will be assessed by Western blot. The panel will include PGC-1α, TOM20, MFN1, OPA1, DRP1, and FIS1. Each protein will be quantified as normalized band intensity relative to the prespecified loading control and expressed in arbitrary units. Results will be reported separately for each protein.
Measured: Baseline, 1 hour, and 3 hours after caffeine or placebo ingestion during each study period
Mitochondrial morphology in PBMCs
Mitochondrial morphology in peripheral blood mononuclear cells (PBMCs) will be evaluated using transmission electron microscopy. A prespecified morphological assessment will be performed using a standardized image-analysis procedure. Mitochondrial morphological features will be quantified and reported separately according to the parameters defined in the statistical analysis plan. Results will be compared between caffeine and placebo conditions across the assessment time points.
Measured: Baseline, 1 hour, and 3 hours after caffeine or placebo ingestion during each study period
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Oct 2026
- Study startSep 2026 (estimated)
- Primary completionDec 2026 (estimated)
- Study completionMar 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Energy MetabolismStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- This is a randomized, double-blind, placebo-controlled, two-period crossover study. Each participant will complete two experimental visits and receive both interventions in randomized order: caffeine and placebo. The two visits will be separated by a 48-hour washout period. During each visit, assessments will be performed before intervention ingestion and 1 and 3 hours after ingestion. Each participant will serve as their own control.
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 12 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Pontificia Universidad Catolica de Chile
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ronald Alejandro Vargas Foitzick, Pontificia Universidad Catolica de Chile
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07873047
- Sponsor's protocol ID
- ID251106012
- Acronym
- MITOCAFFEINE
- Status last verified
- Oct 2026
- First submitted
- 1 Oct 2026
- Last updated
- 14 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: De-identified individual participant data underlying the results reported in the primary publication will be shared. The dataset may include participant-level data on resting energy expenditure, substrate utilization, gas exchange variables, plasma metabolic markers, and peripheral blood mononuclear cell mitochondrial respiration, mitochondrial protein expression, and mitochondrial morphology outcomes. Direct identifiers, indirect identifiers that could reasonably permit re-identification, dates of study visits, and the re-identification key will not be shared. No identifiable biological samples will be shared.
Study at a glance
From the registry record, last updated by the sponsor on 14 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efectos Agudos Del Consumo de cafeína en el Uso de Sustratos y en la función Mitocondrial en células Mononucleares de Sangre periférica
- ClinicalTrials.gov ID
- NCT07873047
- Acronym / sponsor ID
- MITOCAFFEINE / ID251106012
- Conditions
- Energy Metabolism
- Keywords
- caffeine, energy metabolism, sustrate utilization, resting metabolic rate, peripheral blood mononuclear cells, PBMC, mitochondrial function, mitochondrial respiratoration
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 12 participants (estimated)
- Lead sponsor
- Pontificia Universidad Catolica de ChileUniversity, hospital or other
- Study start
- Sep 2026 (estimated)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Mar 2027 (estimated)
- First posted
- 14 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This randomized, double-blind, placebo-controlled crossover study will evaluate the acute effects of caffeine consumption on substrate utilization, resting energy metabolism, and mitochondrial function in peripheral blood mononuclear cells (PBMCs) in healthy young adults. Approximately 10 healthy men and women aged 18 to 35 years will participate. Each participant will complete two experimental visits, receiving caffeine in one visit and placebo in the other, in randomized order. The two visits will be separated by a 48-hour washout period. Participants will attend the laboratory after an overnight fast of approximately 14 hours and will abstain from caffeine, alcohol, and intense physical activity before each visit. Resting gas exchange will be measured before ingestion and 1 and 3 hours after caffeine or placebo administration. Blood samples will be collected at the same time points to isolate PBMCs and obtain plasma for metabolic analyses. Mitochondrial function will be assessed by high-resolution respirometry, and mitochondrial dynamics and morphology will be evaluated using protein analyses and transmission electron microscopy. The study will determine whether acute caffeine consumption alters resting substrate utilization and mitochondrial responses in PBMCs in healthy young adults.
Detailed description
Caffeine is one of the most widely consumed psychoactive compounds and is commonly used because of its stimulant and metabolic effects. By antagonizing adenosine receptors, caffeine may increase sympathetic activity, promote the mobilization of free fatty acids, and alter energy metabolism. Mitochondria are central regulators of cellular energy production, and mitochondrial function and dynamics may respond to changes in nutrient availability and metabolic stress. Peripheral blood mononuclear cells (PBMCs) provide a minimally invasive cellular model that may reflect systemic metabolic responses in humans. However, the acute effects of caffeine on substrate utilization and mitochondrial function and dynamics in human PBMCs remain insufficiently characterized.
This study will use a randomized, double-blind, placebo-controlled, crossover design. Approximately 10 healthy adults aged 18 to 35 years will be recruited. Eligible participants will have a body mass index between 18.5 and 27 kg/m², will not smoke, will not be chronic caffeine consumers exceeding 200 mg/day, and will not use medications or supplements known to affect energy metabolism. Individuals with chronic metabolic, cardiovascular, or inflammatory diseases; recent use of antioxidant supplements or ergogenic substances; or known caffeine hypersensitivity or previous adverse reactions to caffeine will be excluded.
Each participant will complete two experimental visits separated by a 48-hour washout period. Before each visit, participants will avoid caffeine, alcohol, and intense physical activity for 24 hours and will attend the laboratory after an overnight fast of approximately 14 hours. After 30 minutes of supine rest under thermoneutral conditions, resting gas exchange will be measured for 30 minutes using a breath-by-breath pulmonary gas-analysis system. A weight-adjusted dose of caffeine, corresponding to approximately 4 to 6 mg/kg of body weight, or placebo will then be administered with approximately 250 mL of water. Resting gas exchange and venous blood samples will be obtained before ingestion and 1 and 3 hours after ingestion.
Blood samples will be collected from the antecubital vein by qualified healthcare personnel. PBMCs will be isolated using a density-gradient method, and plasma will be obtained for analysis of glucose, lactate, lipid profile, insulin, and non-esterified fatty acids. Mitochondrial respiration in PBMCs will be assessed using high-resolution respirometry, including basal respiration, maximal respiratory capacity, and mitochondrial ATP-linked respiration. Mitochondrial biogenesis, mass, fusion, and fission will be evaluated by assessing PGC-1α, TOM20, MFN1, OPA1, DRP1, and FIS1 protein expression. Mitochondrial morphology will be examined using transmission electron microscopy.
The primary objective is to determine the acute effect of caffeine on mitochondrial function in PBMCs. Additional objectives are to evaluate its effects on resting energy metabolism, substrate utilization, plasma metabolic markers, mitochondrial dynamics, and mitochondrial morphology. Participants will receive a snack at the end of each experimental visit.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- This is a randomized, double-blind, placebo-controlled, two-period crossover study. Each participant will complete two experimental visits and receive both interventions in randomized order: caffeine and placebo. The two visits will be separated by a 48-hour washout period. During each visit, assessments will be performed before intervention ingestion and 1 and 3 hours after ingestion. Each participant will serve as their own control.
| Arm | Type | Receives |
|---|---|---|
| Caffeine followed by Placebo | Experimental | Dietary Supplement: Caffeine (5 mg/kg), Other: PlaceboParticipants assigned to this sequence will receive caffeine during the first experimental visit and placebo during the second experimental visit. The visits will be separated by a 48-hour washout period. Resting gas exchange and venous blood samples will be collected before intervention ingestion and 1 and 3 hours after ingestion during each study period. |
| Placebo followed by Caffeine | Placebo comparator | Dietary Supplement: Caffeine (5 mg/kg), Other: PlaceboParticipants assigned to this sequence will receive placebo during the first experimental visit and caffeine during the second experimental visit. The visits will be separated by a 48-hour washout period. Resting gas exchange and venous blood samples will be collected before intervention ingestion and 1 and 3 hours after ingestion during each study period. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Healthy adults aged 18 to 65 years.
- Body mass index between 18.5 and 27 kg/m².
- Non-smokers.
- Habitual caffeine intake of 200 mg/day or less.
- No use of medications or supplements known to affect energy metabolism.
Key exclusion criteria (3 listed)
- Chronic metabolic, cardiovascular, or inflammatory disease.
- Use of antioxidant supplements or ergogenic substances within the 4 weeks before participation.
- Known hypersensitivity to caffeine or history of adverse effects after caffeine consumption.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Caffeine (5 mg/kg)Caffeine will be administered orally as a single weight-adjusted dose of 5 mg/kg body weight in an opaque capsule with approximately 250 mL of water. It will be administered immediately after baseline measurements during one experimental visit. Participants will receive caffeine in one of the two study periods according to the randomized crossover sequence. Resting gas exchange and venous blood samples will be collected before ingestion and 1 and 3 hours after ingestion. | Dietary supplement | Caffeine followed by Placebo, Placebo followed by Caffeine |
| PlaceboThe placebo will consist of an inert substance administered orally in an opaque capsule matched in appearance to the caffeine capsule, with approximately 250 mL of water. It will be administered immediately after baseline measurements during one experimental visit. Participants will receive placebo in one of the two study periods according to the randomized crossover sequence. | Other | Caffeine followed by Placebo, Placebo followed by Caffeine |
Primary outcome
Basal mitochondrial respiration in PBMCs
Time frame: Baseline, 1 hour, and 3 hours after caffeine or placebo ingestion during each study period
Basal mitochondrial respiration in peripheral blood mononuclear cells (PBMCs) will be assessed as part of a complete high-resolution mitochondrial respirometry protocol using the Oroboros O2k system. Basal oxygen consumption will be measured before addition of respiratory modulators and expressed as oxygen consumption rate in pmol O2/cells
Maximal mitochondrial respiratory capacity in PBMCs
Time frame: Baseline, 1 hour, and 3 hours after caffeine or placebo ingestion during each study period
Maximal mitochondrial respiratory capacity will be determined as part of the complete high-resolution mitochondrial respirometry protocol in PBMCs using the Oroboros O2k system. It will be expressed as maximal oxygen consumption rate in pmol O2/cells
9 secondary outcomes
Resting energy expenditure and substrate utilization
Time frame: Baseline, 1 hour, and 3 hours after caffeine or placebo ingestion during each study period
Fat oxidation rate during resting gas exchange
Time frame: Baseline, 1 hour, and 3 hours after caffeine or placebo ingestion during each study period
Carbohydrate oxidation rate during resting gas exchange
Time frame: Baseline, 1 hour, and 3 hours after caffeine or placebo ingestion during each study period
Plasma glucose concentration
Time frame: Baseline, 1 hour, and 3 hours after caffeine or placebo ingestion during each study period
Plasma lactate concentration
Time frame: Baseline, 1 hour, and 3 hours after caffeine or placebo ingestion during each study period
Plasma insulin concentration
Time frame: Baseline, 1 hour, and 3 hours after caffeine or placebo ingestion during each study period
Plasma non-esterified fatty acid concentration
Time frame: Baseline, 1 hour, and 3 hours after caffeine or placebo ingestion during each study period
Mitochondrial dynamics-related protein expression in PBMCs
Time frame: Baseline, 1 hour, and 3 hours after caffeine or placebo ingestion during each study period
Mitochondrial morphology in PBMCs
Time frame: Baseline, 1 hour, and 3 hours after caffeine or placebo ingestion during each study period
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Oct 2026.
- Individual participant dataSharing planned: Yes. De-identified individual participant data underlying the results reported in the primary publication will be shared. The dataset may include participant-level data on resting energy expenditure, substrate utilization, gas exchange variables, plasma metabolic markers, and peripheral blood mononuclear cell mitochondrial respiration, mitochondrial protein expression, and mitochondrial morphology outcomes. Direct identifiers, indirect identifiers that could reasonably permit re-identification, dates of study visits, and the re-identification key will not be shared. No identifiable biological samples will be shared.
Related trials for Energy Metabolism
RecruitingObservational study
Within-Individual Variability of Resting Metabolic Rate Over 12 Weeks
Resting Metabolic Rate, Energy Metabolism
Recruiting
GENESIS: Genotype Guided - Natriuretic Peptides - Cardiometabolic Health Study
Cardiovascular Diseases, Natriuretic Peptides
Not yet recruiting
Effects of Acute Exercise in Fasting and Fed States in Individuals With Different Aerobic Fitness Levels
Physical Fitness, Mitochondrial Function, Bioenergetics
Enrolling by invitation
Observing Performance of Haptic Vibrotactile Trigger Technology by Measuring Changes in Resting Metabolic Rate: Assessment and Analysis
Resting Metabolic Rate, Energy Metabolism
RecruitingPhase 2
NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals
Diabetes Mellitus, Cardiovascular Diseases
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A study testing Caffeine (5 mg/kg) in people with Energy Metabolism, run by Pontificia Universidad Catolica de Chile.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 14 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ronald A Vargas-Foitzick, PhD (+56936273431, rvargaf@uc.cl), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Basal mitochondrial respiration in PBMCs (time frame: Baseline, 1 hour, and 3 hours after caffeine or placebo ingestion during each study period). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Oct 2026; AzTrials last refreshed its copy on 26 Oct 2026.